07:30 AM EDT, 08/05/2024 (MT Newswires) -- BioCryst Pharmaceuticals ( BCRX ) reported a Q2 adjusted loss Monday of $0.06 per diluted share, narrowing from a loss of $0.24 a year earlier.

Analysts polled by Capital IQ expected a normalized loss of $0.16.

Revenue for the quarter ended June 30 was $109.3 million, up from $82.5 million a year earlier.

Analysts surveyed by Capital IQ expected $98.3 million.

The company raised its 2024 global net Ordaleyo revenue outlook to now be between $420 million and $435 million from the prior guidance of $390 million to $400 million. Analysts surveyed by Capital IQ expect $401.4 million.